Bausch + Lomb Introduces New PreserVision Eye Vitamin and Mineral Supplement
This builds on the original, clinically proven Age-Related Eye Disease Study (AREDS) formula, replacing beta-carotene with lutein (10mg) and zeaxanthin (2mg) and adding omega-3 fatty acids (1000 mg) per daily dosage.
12 Apr 2010 --- Bausch + Lomb announces the U.S. launch of PreserVision Eye Vitamin and Mineral Supplement AREDS 2 formula. This builds on the original, clinically proven Age-Related Eye Disease Study (AREDS) formula, replacing beta-carotene with lutein (10mg) and zeaxanthin (2mg) and adding omega-3 fatty acids (1000 mg) per daily dosage. The product will be on retail shelves in early May, 2010.
Scientific studies show that the inclusion of high levels of omega-3 fatty acids, lutein and zeaxanthin in the diet supports eye health. Age-related macular degeneration (AMD) is the number one cause of severe vision loss and blindness in the United States for people over the age of 50.
The AREDS2 study, which is currently ongoing and expected to complete in 2013, is sponsored by the National Eye Institute/National Institute of Health and is the second nationwide clinical study to determine whether a combination of vitamins and minerals can further slow the progression of vision loss from AMD. PreserVision AREDS 2 formula is one of many formulas that are being evaluated in this study.